Thomas Aller, OD, provides in-depth overviews of each myopia management option—pharmacologic therapy, soft contact lenses, orthokeratology, spectacle lenses, and environmental and behavioral interventions—so clinicians can not only provide the right option to each patient, but also address the larger economic and societal burdens of myopia.
Myopia is now recognized as a progressive disease with significant risks for ocular pathology, including retinal detachment and glaucoma.
2
Public health organizations advocate for myopia management to delay onset and slow progression, emphasizing its importance in standard eye care.
3
Economic modeling indicates that myopia incurs substantial productivity losses globally, affecting both individuals and society.
4
Low-dose atropine is a versatile pharmacologic therapy for myopia control, particularly effective in younger children and those with rapid progression.
5
Axial length measurements and the AL/CR ratio are critical for risk assessment in myopia management, aiding in early intervention decisions.
